nach oben

Erschienen in:

01.05.2006 | Review Article

Cost Effectiveness of Preventive Interventions in Type 2 Diabetes Mellitus

A Systematic Literature Review

verfasst von: Sylvia M. C. Vijgen, Mirjam Hoogendoorn, Caroline A. Baan, G. Ardine de Wit, Wien Limburg, Talitha L. Feenstra

Erschienen in: PharmacoEconomics | Ausgabe 5/2006

Einloggen, um Zugang zu erhalten

Abstract

A systematic review of the literature was conducted to give an overview of economic evaluations of preventive interventions in type 2 diabetes mellitus. The interventions were sorted by type of preventive intervention (primary, secondary or tertiary) and by category (e.g. education, medication for hypertension). Several databases were searched for studies published between January 1990 and May 2004 on the three types of preventive intervention. For each study selected, inclusion of specific components from a standardised list of items, including quality, was recorded in a database. Summary tables were generated based on the database.

A number of conclusions were drawn from this review. The most important was that strict blood pressure control was a more cost-effective intervention than less strict control, as shown by six studies reporting cost savings to very low costs per life-year gained. Primary and secondary prevention of type 2 diabetes were also highly cost effective, but these results were based on very few studies. Medications to reduce weight and hyperglycaemia together were cost effective compared with conventional interventions. Finally, the separate results regarding medications to reduce weight, hyperglycaemia and hypercholesterolaemia varied enormously, thus no conclusion could be drawn and further economic analysis is required.

Wild S, Roglic G, Green A, et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27 (5): 1047–1053PubMedCrossRef

Harris MI, Aegal KM, Cowie CC, et al. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in US adults: the Third National Health and Nutrition Examination Survey, 1988–1994. Diabetes Care 1998 Apr; 21 (4): 518–524PubMedCrossRef

Borch-Johnsen K, Lauritzen T, Glumer C, et al. Screening for type 2 diabetes: should it be now? Diabet Med 2003; 20 (3): 175–181PubMedCrossRef

American Diabetes Association. Screening for type 2 diabetes. Diabetes Care 2004; 27 Suppl. 1: S11–S14CrossRef

van Os N, Niessen LW, Koopmanschap MA, et al. Detailed analysis of the societal costs of diabetes mellitus [in Dutch]. Ned Tijdschr Geneeskd 2000; 144 (18): 842–846PubMed

Raikou M, McGuire A. The economics of screening and treatment in type 2 diabetes mellitus. Pharmacoeconomics 2003; 21 (8), 543–564PubMedCrossRef

Klonoff DC, Schwartz DM. An economic analysis of interventions for diabetes. Diabetes Care 2000; 23 (3): 390–404PubMedCrossRef

Zhang P, Engelgau M, Norris SL. Application of economic analysis to diabetes and diabetes care. Ann Intern Med 2004; 140 (11): 972–977PubMed

Clarke P, Gray A, Adler A, et al. Cost-effectiveness analysis of intensive blood-glucose control with metformin in overweight patients with type II diabetes (UKPDS No. 51). Diabetologia 2001; 44 (3): 298–304PubMedCrossRef

10.

Gray A, Clarke P, Raikou M, et al. An economic evaluation of atenolol vs captopril in patients with type 2 diabetes (UKPDS 54). Diabet Med 2001; 18 (6): 438–444PubMedCrossRef

11.

UK Prospective Diabetes Study Group. Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40. BMJ 1998 Sep 12; 317 (7160): 720–726CrossRef

12.

Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. BMJ 1996 Aug; 313: 275–283PubMedCrossRef

13.

O’Connor PJ, Rush W A, Cherney LM, et al. Screening for diabetes mellitus in high-risk patients: cost, yield, and acceptability. Eff Clin Pract 2001; 4 (6): 271–277PubMed

14.

Law AV, Pathak DS, Segraves AM, et al. Cost-effectiveness analyses of the conversion of patients with non-insulin-dependent diabetes mellitus from glipizide to glyburide and of the accompanying pharmacy follow-up clinic. Clin Ther 1995; 17 (5), 977–987PubMedCrossRef

15.

Trento M, Passera P, Bajardi M, et al. Lifestyle intervention by group care prevents deterioration of type II diabetes: a 4-year randomized controlled clinical trial. Diabetologia 2002; 45 (9): 1231–1239PubMedCrossRef

16.

Glasgow RE, Chance PAL, Toobert DJ, et al. Long-term effects and costs of brief behavioural dietary intervention for patients with diabetes delivered from the medical office. Patient Educ Couns 1997; 32 (3): 175–184PubMedCrossRef

17.

The Diabetes Prevention Program Research Group. Within-trial cost-effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care 2003; 26 (9), 2518–2523CrossRef

18.

Gray A, Raikou M, McGuire A, et al. Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: economic analysis alongside randomized controlled trial (UKPDS 41). The United Kingdom Prospective Diabetes Study (UKPDS) Group. BMJ 2000; 320: 1373–1378PubMedCrossRef

19.

Jonsson B, Hansson L, Stalhammar NO. Health economics in the Hypertension Optimal Treatment (HOT) study: costs and cost-effectiveness of intensive blood pressure lowering and low-dose aspirin in patients with hypertension. J Intern Med 2003; 253 (4): 472–480PubMedCrossRef

20.

Brown RR. Cost-effectiveness and clinical outcomes of metformin or insulin add-on therapy in adults with type 2 diabetes. Am J Health Syst Phann 1998; 55 (24 Suppl. 4): S24–S27

21.

Souchet T, Durand Zaleski I, Hannedouche T, et al. An economic evaluation of Losartan therapy in type 2 diabetic patients with nephropathy: an analysis of the RENAAL study adapted to France. Diabetes Metab 2003; 29 (1): 29–35PubMedCrossRef

22.

Hoerger TJ, Harris R, Hicks KA, et al. Screening for type 2 diabetes mellitus: a cost-effectiveness analysis. Ann Intern Med 2004; 140 (9): 689–699PubMed

23.

Segal L, Dalton AC, Richardson J. Cost-effectiveness of the primary prevention of non-insulin dependent diabetes mellitus. Health Promot Int 1998; 13 (3): 197–209CrossRef

24.

Elliott WJ, Weir DR, Black HR. Cost-effectiveness of the lower treatment goal (of JNC VI) for diabetic hypertensive patients: Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 2000; 160 (9): 1277–1283PubMedCrossRef

25.

Gozzoli V, Palmer AJ, Brandt A, et al. Economic and clinical impact of alternative disease management strategies for secondary prevention in type 2 diabetes in the Swiss setting. Schweiz Med Wochenschr 2001; 131 (21–22): 303–310

26.

Palmer AJ, Roze S, Valentine WJ, et al. Intensive lifestyle changes or metformin in patients with impaired glucose tolerance: modeling the long-term health economic implications of the diabetes prevention program in Australia, France, Germany, Switzerland, and the United Kingdom. Clin Ther 2004; 26: 304–321PubMedCrossRef

27.

The CDC Diabetes Cost-Effectiveness Group. Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes. JAMA 2002; 287 (19): 2542–2551CrossRef

28.

Jonsson B, Cook JR, Pedersen TR. The cost-effectiveness of lipid lowering in patients with diabetes: results from the 4S trial. Diabetologia 1999; 42 (11): 1293–1301PubMedCrossRef

29.

Lamotte M, Annemans L, Lefever A, et al. A health economic model to assess the long-term effects and cost-effectiveness of orlistat in obese type 2 diabetic patients. Diabetes Care 2002; 25 (2), 303–308PubMedCrossRef

30.

Coyle D, Palmer AJ, Tam R. Economic evaluation of pioglitazone hydrochloride in the management of type 2 diabetes mellitus in Canada. Pharmacoeconomics 2002; 20 Suppl. 1: 31–42PubMedCrossRef

31.

Eastman RC, Javitt JC, Herman WH, et al. Model of complications of NIDDM: II. Analysis of the health benefits and cost-effectiveness of treating NIDDM with the goal of nonnoglycemia. Diabetes Care 1997; 20 (5): 735–744PubMedCrossRef

32.

Maetzel A, Ruof J, Covington M, et al. Economic evaluation of orlistat in overweight and obese patients with type 2 diabetes mellitus. Pharmacoeconomics 2003; 21 (7): 501–512PubMedCrossRef

33.

Henriksson F. Applications of economic models in healthcare: the introduction of pioglitazone in Sweden. Phannacoeconomics 2002; 20 Suppl. 1: 43–53CrossRef

34.

Palmer AJ, Sendi PP, Spinas GA. Applying some UK Prospective Diabetes Study results to Switzerland: the cost-effectiveness of intensive glycaemic control with metformin versus conventional control in overweight patients with type-2 diabetes. Schweiz Med Wochenschr 2000; 130 (27–28): 1034–1040PubMed

35.

Salas M, Ward A, Caro J. Health and economic effects of adding nateglinide to metformin to achieve dual control of glycosylated hemoglobin and postprandial glucose levels in a model of type 2 diabetes mellitus. Clin Ther 2002; 24 (10): 1690–1705PubMedCrossRef

36.

Caro JJ, Klittich WS, Raggio G, et al. Economic assessment of troglitazone as an adjunct to sulfonylurea therapy in the treatment of type 2 diabetes. Clin Ther 2000; 22 (1): 116–127PubMedCrossRef

37.

Alrmrand B, Johannesson M, Sjostrand B, et al. Cost-effectiveness of intense insulin treatment after acute myocardial infarction in patients with diabetes mellitus: results from the DIGAMI study. Eur Heart J 2000; 21 (9): 733–739CrossRef

38.

Neeser K, Lubben G, Siebert U, et al. Cost effectiveness of combination therapy with pioglitazone for type 2 diabetes mellitus from a German statutory healthcare perspective. Pharmacoeconomics 2004; 22 (5): 321–341PubMedCrossRef

39.

Casciano J, Doyle J, Casciano R, et al. The cost-effectiveness of doxazosin for the treatment of hypertension in type II diabetic patients in the UK and Italy. Int J Clin Pract 2001; 55 (2): 84–92PubMed

40.

Rodby RA, Chiou CF, Borenstein J, et al. The cost-effectiveness of irbesartan in the treatment of hypertensive patients with type 2 diabetic nephropathy. Clin Ther 2003; 25 (7): 2102–2119PubMedCrossRef

41.

Grover SA, Coupal L, Zowall H, et al. How cost-effective is the treatment of dyslipidemia in patients with diabetes but without cardiovascular disease? Diabetes Care 2001; 24 (1): 45–50PubMedCrossRef

42.

Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group [published erratum appears in BMJ 1999 Jan 2; 318 (7175): 29]. BMJ 1998 Sep 12; 317 (7160): 703–13

43.

Grimm RH, Flack JM, Grandits GA, et al. Long-term effects on plasma lipids of diet and drugs to treat hypertension. JAMA 1996; 275: 1549–1556PubMedCrossRef

44.

Anderson KM, Odell PM, Wilson PWF, et al. Cardiovascular disease risk profiles. Am Heart J 1990; 121: 293–298CrossRef

45.

UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) [published erratum appears in Lancet 1999 Aug 14; 354 (9178): 602]. Lancet 1998 Sep 12; 352 (9131): 837–853CrossRef

46.

The West of Scotland Coronary Prevention Study Group. Baseline risk factors and their association with outcome in the West of Scotland Coronary Prevention Study. Am J Cardiol 1997 Mar 15; 79 (6): 756–762CrossRef

47.

Klein R, Klein BE, Moss SE, et al. The Wisconsin epidemiologic study of diabetic retinopathy: IX. Four-year incidence and progression of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol 1989 Feb; 107 (2): 237–243PubMedCrossRef

48.

Ballard DJ, Melton LJ III, Dwyer MS, et al. Risk factors for diabetic retinopathy: a population-based study in Rochester, Minnesota. Diabetes Care 1986 Jul–Aug; 9 (4): 334–342PubMedCrossRef

49.

The Diabetes Control and complications Trial Research Group. Lifetime benefits and costs of intensive therapy as practiced in the diabetes control and complications trial [published erratum appears in JAMA 1997 Jul 2; 278 (1): 25]. JAMA 1996 Nov 6; 276 (17): 1409–1415CrossRef

50.

Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet. 1998; 351: 1755–1762PubMedCrossRef

51.

Humphrey LL, Ballard DJ, Frohnert PP, et al. Chronic renal failure in non-insulin-dependent diabetes mellitus: a population-based study in Rochester, Minnesota. Ann Intern Med 1989 Nov 15; 111 (10): 788–796PubMed

52.

Taylor TN, Davis PH, Torner JC, et al. Lifetime cost of stroke in the United States. Stroke 1996 Sep; 27 (9): 1459–1466PubMedCrossRef

53.

Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke, and coronary heart disease: part 2. Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990 Apr 7; 335 (8693): 827–838PubMedCrossRef

54.

Hollander PA, Elbein SC, Hirsch IB, et al. Role of orlistat in the treatment of obese patients with type 2 diabetes: a 1-year randomized double-blind study. Diabetes Care 1998 Aug; 21 (8), 1288–1294PubMedCrossRef

55.

Heymsfield SB, Segal KR, Hauptman J, et al. Fffects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults. Arch Intern Med 2000 May 8; 160 (9), 1321–1326PubMedCrossRef

56.

UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352 (9131): 854–865CrossRef

57.

Koskinen P, Manttari M, Manninen V, et al. Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study. Diabetes Care 1992 Jul; 15 (7): 820–825PubMedCrossRef

58.

Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascularcomplications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000 Aug 12; 321 (7258): 405–412PubMedCrossRef

59.

Lindgarde F. The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: the Swedish Multimorbidity Study. J Intern Med 2000 Sep; 248 (3): 245–254PubMedCrossRef

60.

Hanefeld M, Sachse G. The effects of orlistat on body weight and glycaemic control in overweight patients with type 2 diabetes: a randomized, placebo-controlled trial. Diabetes Obes Metab 2002 Nov; 4 (6): 415–423PubMedCrossRef

61.

Kelley DE, Bray GA, Pi-Sunyer FX, et al. Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: a 1-year randomized controlled trial. Diabetes Care 2002 Jun; 25 (6): 1033–1041PubMedCrossRef

62.

Miles JM, Leiter L, Hollander P, et al. Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metfornin. Diabetes Care 2002 Jul; 25 (7): 1123–1128PubMedCrossRef

63.

Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin: Diabetes Prevention Program Research Group. N Engl J Med 2002 Feb 7; 346 (6): 393–403PubMedCrossRef

64.

Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes: Collaborative Study Group. N Engl J Med 2001 Sep 20; 345 (12): 851–860PubMedCrossRef

65.

Rodby RA, Rohde RD, Clarke WR, et al. The Irbesartan type II diabetic nephropathy trial: study design and baseline patient characteristics. For the Collaborative Study Group. Nephrol Dial Transplant 2000 Apr; 15 (4): 487–497PubMedCrossRef

66.

Balkau B, Eschwege E, Papoz L, et al. Risk factors for early death in non-insulin dependent diabetes and men with known glucose tolerance status. BMJ 1993; 307 (6899): 295–299PubMedCrossRef

67.

Panzram G. Mortality and survival in type 2 (non-insulin-dependent) diabetes mellitus [published erratum appears in Diabetologia 1987; 30 (5): 364]. Diabetologia 1987; 30 (3): 123–131PubMedCrossRef

68.

Simons LA, McCallum J, Freidlander Y, et al. Diabetes, mortality and coronary heart disease in the prospective Dubbo study of Australian elderly. Aust N Z J Med 1996; 26 (1): 66–74PubMedCrossRef

69.

Drenick EJ, Bale GS, Seltzer F, et al. Excessive mortality and causes of death in morbidly obese men. JAMA 1980; 243 (5): 443–445PubMedCrossRef

70.

Manson JE, Stampfer MJ, Hennekens CH, et al. Body weight and longevity: a reassessment. JAMA 1987; 257 (3): 353–358PubMedCrossRef

71.

Rissanen A, Heliovaara M, P Knekt, et al. Risk of disability and mortality due to overweight in a Finnish population. BMJ 1990; 301 (6756): 835–837PubMedCrossRef

72.

Body weight and mortality: a 27-year follow-up of middle aged men. JAMA 1993; 270 (23): 2823–8

73.

Eriksson KF, Lindgarde F. Prevention of type 2 (non-insulindependent) diabetes mellitus by diet and physical exercise: the 6-year Malmo feasibility study. Diabetologia 1991 Dec; 34 (12), 891–898PubMedCrossRef

74.

Australian Bureau of Statistics (1995). Deaths, Australia (1994). Catalogue No. 3302.0. Australian Government Publishing Service, Canberra

75.

Haffner SM, Alexander CM, Cook TJ, et al. Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analyses in the Scandinavian Simvastatin Survival Study. Arch Intern Med 1999 Dec 13–27; 159 (22): 2661–2667PubMedCrossRef

76.

Grover SA, Coupal L, Paquet S, et al. Cost-effectiveness of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in the secondary prevention of cardiovascular disease: forecasting the incremental benefits of preventing coronary and cerebrovascular events. Arch Intern Med 1999 Mar 22; 159 (6): 593–600PubMedCrossRef

77.

Grover SA, Paquet S, Levinton C, et al. Estimating the benefits of modifying risk factors of cardiovascular disease: a comparison of primary vs secondary prevention. Arch Intern Med 1998 Mar 23; 158 (6): 655–662PubMedCrossRef

78.

Grover SA, Palmer CS, Coupal L. Serum lipid screening to identify high-risk individuals for coronary death: the results of the Lipid Research Clinics prevalence cohort. Arch Intern Med 1994 Mar 28; 154 (6): 679–684PubMedCrossRef

79.

Horton ES, Clinkingbeard C, Gatlin M, et al. Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes. Diabetes Care 2000 Nov; 23 (11): 1660–1665PubMedCrossRef

80.

The Diabetes Control and complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulindependent diabetes mellitus. N Engl J Med 1993 Sep 30; 329 (14), 977–986CrossRef

81.

Horton ES, Whitehouse F, Ghazzi MN, et al. Troglitazone in combination with sulfonylurea restores glycemic control in patients with type 2 diabetes: the Troglitazone Study Group. Diabetes Care 1998 Sep; 21 (9): 1462–1469PubMedCrossRef

82.

Palmer AJ, Weiss C, Sendi PP, et al. The cost-effectiveness of different management strategies for type I diabetes: a Swiss perspective. Diabetologia 2000 Jan; 43 (1): 13–26PubMedCrossRef

83.

Aronoff S, Rosenblatt S, Braithwaite S, et al. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group. Diabetes Care 2000 Nov; 23 (11): 1605–1611PubMedCrossRef

84.

Johansen K. Efficacy of metformin in the treatment of NIDDM: meta-analysis. Diabetes Care 1999 Jan; 22 (1): 33–37PubMedCrossRef

85.

Hermann LS, Schersten B, Bitzen PO, et al. Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations: a double-blind controlled study. Diabetes Care 1994 Oct; 17 (10): 1100–1109PubMedCrossRef

86.

Matthews DR, Cull CA, Stratton IM, et al. UKPDS 26: sulphonylurea failure in non-insulin-dependent diabetic patients over six years. UK Prospective Diabetes Study (UKPDS) group. Diabet Med 1998 Apr; 15 (4): 297–303PubMedCrossRef

87.

Henriksson F, Agardh CD, Berne C, et al. Direct medical costs for patients with type 2 diabetes in Sweden. J Intern Med 2000 Nov; 248 (5): 387–396PubMedCrossRef

88.

UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998 Sep 12; 317 (7160): 713–720CrossRef

89.

Bundesamt fur Statistik. Stebetafeln fur die Schweiz 1988/1993. Bern: 1996

90.

Arbeitsgruppe der Schweizerischen Diabetes-Stiftung. Die St. Vincent-Deklaration: eine Umfrage zur Diabetiker-Betreuung in der Schweiz. Schweizerische Aerztezeitung 1996; 77: 668–675

91.

Kipnes MS, Krosnick A, Rendell MS, et al. Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study. Am J Med 2001 Jul; 111 (1): 10–17PubMedCrossRef

92.

Einhorn D, Rendell M, Rosenzweig J, et al. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group. Clin Ther 2000 Dec; 22 (12): 1395–1409PubMedCrossRef

93.

Piehlmeier W, Renner R, Schramm W, et al. Screening of diabetic patients for microalbuminuria in primary care: the PROSIT-Project. Proteinuria Screening and Intervention. Exp Clin Endocrinol Diabetes 1999; 107 (4): 244–251PubMedCrossRef

94.

Malrrberg K, Ryden L, Efendic S, et al. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. J Am Coll Cardiol 1995 Jul; 26 (1): 57–65CrossRef

95.

Malrrberg K. Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) study group. BMJ 1997 May 24; 314 (7093): 1512–1515CrossRef

96.

CDC Diabetes Cost-Effectiveness Study Group. The cost-effectiveness of screening for type 2 diabetes. JAMA 1998; 280 (20): 1757–1763CrossRef

97.

Welte R, Feenstra T, Jager H, et al. A decision chart for assessing and improving the transferability of economic results between countries. Pharmacoeconomics 2004; 22 (13): 857–876PubMedCrossRef

Titel: Cost Effectiveness of Preventive Interventions in Type 2 Diabetes Mellitus
A Systematic Literature Review
verfasst von: Sylvia M. C. Vijgen
Mirjam Hoogendoorn
Caroline A. Baan
G. Ardine de Wit
Wien Limburg
Talitha L. Feenstra
Publikationsdatum: 01.05.2006
Verlag: Springer International Publishing
Erschienen in: PharmacoEconomics / Ausgabe 5/2006
Print ISSN: 1170-7690
Elektronische ISSN: 1179-2027
DOI: https://doi.org/10.2165/00019053-200624050-00002

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2006

The Authors’ Reply

Economic Evaluation of Weekly Epoetin Alfa versus Biweekly Darbepoetin Alfa for Chemotherapy-Induced Anaemia

Letrozole

Comprehensive Decision-Analytic Model and Bayesian Value-of-Information Analysis

Cost Considerations in the Medical Management of Glaucoma in the US: Estimated Yearly Costs and Cost Effectiveness of Bimatoprost Compared with Other Medications

Encouraging Smokers to Quit